NCT04079712 2026-03-18
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
7 trialsNCT03670056 2025-07-20
Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy
Yale University
Phase 2 Active not recruiting
NCT02046733 2024-11-08
STIMULI
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT03083691 2024-01-17
BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer
Lung Cancer Group Cologne
Phase 2 Completed
NCT03406715 2023-03-30
Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00527735 2018-07-18
Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)
Bristol-Myers Squibb
Phase 2 Completed
NCT01331525 2016-04-14
ICE
University Hospital Southampton NHS Foundation Trust
Phase 2 Completed